Zcash Boosts Cypherpunk Profit
Cypherpunk Records $39.4 Million Q2 Profit, Reversing Losses with Zcash Treasury Gains
Key Points
Cypherpunk posted a $77.2 million net loss in Q1 2026, followed by a $77.6 million unrealized loss tied to Zcash (ZEC) price declines, illustrating the downside risk of a crypto-treasury strategy even as Q2 profitability emerged.
Winklevoss Capital spearheaded a private placement that helped fund Cypherpunk's ZEC accumulation, signaling backing from a prominent crypto-focused investor for its treasury strategy.
Cypherpunk reduced R&D spending sharply in Q2 2026 to $0.2 million (down from $10.5 million year-over-year), while general and administrative costs rose to $4.5 million due to higher stock-based compensation and payroll.
Phase 2 DeFiance results for sirexatamab were published, and the FDA granted Fast Track designation for a registrational Phase 3 trial in DKK1-high metastatic colorectal cancer, with regulatory alignment reached on the Phase 3 design.
Cypherpunk indicated an ongoing strategic process to fund its biotechnology operations through equity, partnerships, or licensing, with no timetable set for any such financing actions.
Cypherpunk Technologies swung from a $16.6 million loss to a $39.4 million profit in Q2 2026, powered almost entirely by a $46 million unrealized gain on its Zcash (ZEC) cryptocurrency holdings, according to Crypto Briefing. The result marks a dramatic reversal for the company, which had posted a $77.2 million net loss just one quarter earlier.
The firm now holds 323,394 ZEC — about 1.92% of the coin's entire circulating supply — valued at roughly $129.4 million, TipRanks reported. The average purchase price was $341.83 per token, meaning the position sits well above cost at current prices.
A $46 Million Zcash Bet Drives the Turnaround
Cypherpunk's profit is almost entirely paper gains. The $46 million figure is an unrealized gain, meaning the company has not sold its ZEC. That distinction matters. Just one quarter ago, a drop in ZEC prices produced a $77.6 million unrealized loss, wiping out the company's bottom line, according to GuruFocus.
Winklevoss Capital backed a private placement that helped fund the ZEC buying spree, Quartr noted. That ties a well-known crypto name to Cypherpunk's treasury strategy. The company holds a $200 million ATM (at-the-market) facility — a tool that lets it sell stock to raise cash — and about $7.6 million in cash to fund at least one year of operations.
Operating Costs Shift as R&D Spending Collapses
Cypherpunk cut research and development spending to just $0.2 million in Q2 2026. That is down from $10.5 million in the same quarter a year ago — a drop of more than 98%, GuruFocus reported. The sharp cut signals a pullback from early-stage science spending.
General and administrative costs moved the other way, rising to $4.5 million. Higher stock-based compensation and payroll drove the increase, according to TipRanks. The net effect was still positive, as the massive ZEC gain far outweighed any rise in overhead.
Biotech Arm Reaches FDA Milestone for Cancer Drug
Cypherpunk is not purely a crypto company. It also runs biotech operations through Leap Therapeutics. The FDA granted Fast Track designation for a Phase 3 trial of sirexatamab, a drug targeting DKK1-high metastatic colorectal cancer, TipRanks reported. Fast Track status speeds the review process for drugs that treat serious conditions.
Phase 2 results from the DeFiance trial were published, and Cypherpunk said it has reached alignment with the FDA on the Phase 3 design, according to Quartr. The company is still searching for ways to fund its biotech unit through equity sales, partnerships, or licensing deals, with no timetable announced.
New Advisor Brought In to Strengthen ZEC Ecosystem Role
Cypherpunk appointed Dev Ojha, founder of Valar Group, as an advisor. The move is meant to boost development within the broader Zcash ecosystem, TipRanks noted. Ojha's role signals that the company sees its ZEC treasury as more than a passive bet — it wants a seat at the table in how Zcash grows.
The company's dual strategy — crypto treasury plus biotech — creates unusual risk. ZEC price swings can erase or create tens of millions in profit within a single quarter, as the past two quarters show. TradingView reported diluted earnings per share of $0.18 for Q2, compared to a loss in the prior-year period.
Sentiment
Mostly PositivePublishers
10
Articles
5
Reach
15
